Biochemically Recurrent Prostate Cancer: Superior Agents to Conventional Imaging - Andrei Iagaru
Dr. Iagaru is an Associate Professor of Radiology - Nuclear Medicine and the Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford Health Care. He completed medical school at Carol Davila University of Medicine, Bucharest, Romania, and an internship at Drexel University College of Medicine, Graduate Hospital, in the Department of Medicine in Philadelphia. He began his residency at the University of Southern California (USC) Keck School of Medicine, Los Angeles, in the Division of Nuclear Medicine, where he was the chief resident. Dr. Iagaru finished his residency and completed a PET/CT fellowship at Stanford University's School of Medicine in the Division of Nuclear Medicine. His research interests include PET/MRI and PET/CT for early cancer detection; clinical translation of novel PET radiopharmaceuticals; peptide-based diagnostic imaging and therapy; and radioimmunotherapy.
Role of MRI in Men on Active Surveillance - Laurence Klotz
A Phase II Study of 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
Metabolically-stabilized 68Ga-NOTA-bombesin for PET Imaging of prostate cancer and influence of protease inhibitor Phosphoramidon.
Radiopharmaceuticals for diagnosis and therapy of neuroendocrine differentiated prostate cancer.